Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells 22,408 Shares

Key Points

• CEO Najat Khan sold 22,408 Recursion Pharmaceuticals shares at an average price of $3.52, generating $78,876.16. The sale, conducted under a pre-arranged Rule 10b5-1 plan, reduced her holdings by 1.07% to 2.07 million shares.
• RXRX shares recently traded at $3.16, near the lower end of their 52-week range of $2.77 to $7.18. The company reported a quarterly loss of $0.25 per share and revenue of $7.67 million, both below analyst expectations.
• Analyst sentiment remains mixed, with a consensus rating of Hold and an average price target of $8.06. Institutional investors own approximately 89.06% of the company, with several major funds increasing their stakes.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CEO Najat Khan sold 22,408 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the sale, the chief executive officer owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX traded down $0.05 during trading hours on Thursday, reaching $3.16. The company's stock had a trading volume of 10,614,265 shares, compared to its average volume of 18,001,195. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $3.32 and a 200 day simple moving average of $3.33. The stock has a market cap of $1.69 billion, a PE ratio of -3.04 and a beta of 1.07. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period last year, the business posted ($0.41) EPS. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RXRX has been the subject of several recent research reports. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 29th. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, August 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $8.06.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 11.2% in the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company's stock worth $152,626,000 after purchasing an additional 3,771,357 shares in the last quarter. State Street Corp raised its stake in shares of Recursion Pharmaceuticals by 38.7% during the fourth quarter. State Street Corp now owns 25,333,888 shares of the company's stock valued at $103,616,000 after purchasing an additional 7,064,963 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Recursion Pharmaceuticals by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company's stock valued at $44,731,000 after purchasing an additional 1,310,695 shares in the last quarter. Norges Bank acquired a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $23,473,000. Finally, Lingotto Investment Management LLP lifted its holdings in Recursion Pharmaceuticals by 34.2% in the fourth quarter. Lingotto Investment Management LLP now owns 4,931,057 shares of the company's stock worth $20,168,000 after purchasing an additional 1,255,980 shares during the period. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.